#186 – Patrick Radden Keefe: The opioid crisis—origin, guilty parties, and the difficult path forward
“Today the opioid crisis is a heroin and fentanyl crisis… absent Oxycontin, we might not be where we are today.” —Patrick Radden Keefe
#185 – Allan Sniderman, M.D.: Cardiovascular disease and why we should change the way we assess risk
“If we’re still saying the same things we said 30 years ago, it could be a problem because we should have learned how to say it better, more accurately.” —Allan Sniderman
#184 – AMA #29: GLP-1 Agonists – The Future of Treating Obesity?
“Getting deeper into how this drug works has certainly made me appreciate its power.” —Peter Attia
#183 – James Clear: Building & Changing Habits
“If you’re going to be building habits anyway, you might as well understand what they are and how they work and how to shape them so that you can be the architect of your habits and not the victim of them.” —James Clear
#182 – David Nutt: Psychedelics & Recreational Drugs
“It turns out that the drugs that have been most vilified and which we’ve been taught are the most dangerous, turned out to be the least dangerous.” —David Nutt
#181 – Robert Gatenby, M.D.: Viewing cancer through an evolutionary lens and why this offers a radically different approach to treatment
“For a century we’ve been looking for magic bullets, but maybe all we need is a series of pretty good bullets.” —Bob Gatenby
#180 – AMA #28: All things testosterone and testosterone replacement therapy
“There were countless other studies to look at, but they all basically point in the same direction, which is testosterone replacement therapy improves lean mass, reduces fat mass, improves strength.” —Peter Attia
#179 – Jeremy Loenneke, Ph.D.: The science of blood flow restriction—benefits, uses, and what it teaches us about the relationship between muscle size and strength
“The real utility of using blood flow restriction is the fact that you can use it with very low loads…we’ve tried to combine it with high loads and in different aspects, and other people have run training studies with it, but it’s not additive; it doesn’t add anything more to high-low training” – Jeremy Loekenne
#178 – Lance Armstrong: The rise, fall, and growth of a cycling legend
“That guy needed to die and a new guy needed to come around.” —Lance Armstrong
#177 – Steven Rosenberg, M.D., Ph.D.: The development of cancer immunotherapy and its promise for treating advanced cancers
“It’s the balance of the aggressive immune reaction against the inhibitory molecules that can prevent that immune reaction that is the holy grail of trying to find effective treatments.” —Steven Rosenberg